Location Los Angeles, California, United States Regions Greater Los Angeles Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn X (Twitter) View on X
Andrew Gray received his doctorate in Genetics, Molecular and Cellular Biology from the University of Southern California. His research has focused on the molecular biology and immunology of tumor microenvironments, with a particular focus on prostate cancer and melanoma. Andrew co-developed a therapeutic vaccine for metastatic prostate cancer
during his doctoral studies. He also identified the mechanisms by which advanced prostate cancers can evade the anti-tumor immune response, and investigated methods to circumvent these mechanisms. This work led to eight peer-reviewed publications, including three as first author. More recently, Andrew has focused on the use of nanoparticle drug delivery to treat cancer. He led the collaborative project between Vali , USC and Harvard that produced VNM-101. He was responsible for securing funding, team management, and the completion of the project’s technical milestones. Andrew is a co-inventor of the targeted cross-linked multilamellar liposome technology that Vali is focused on developing for clinical use. Andrew has undertaken training in Biosciences Management from the Keck Graduate Institute (Claremont, California), in Entrepreneurship for Biomedical Scientists at USC (Los Angeles, California), and in Safety Evaluation during Drug Development from USC (Los Angeles, California).
